Haiqing Bai

Haiqing Bai currently serves as the Director of Preclinical Development at Xellar Biosystems, a position held since July 2022. Previously, Haiqing Bai was a Wyss Technology Development Fellow and Postdoctoral Fellow at the Wyss Institute at Harvard University from September 2018 to July 2022. Prior experience includes serving as a Graduate Research Assistant at the University of Rochester Medical Center from September 2012 to July 2018, where work focused on gene therapy for Acute Respiratory Distress Syndrome under Dr. David Dean. Earlier, Haiqing Bai contributed as an Undergraduate Research Assistant at the University of Science and Technology of China from 2010 to 2012, improving the affinity of an anti-Her2 antibody in Dr. Jing Liu's lab. Academic qualifications include a Doctor of Philosophy in Pathology/Experimental Pathology from the University of Rochester (2012-2018) and a Bachelor of Science in Systems Biology from the University of Science and Technology of China (2008-2012).